These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 17070570)
41. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. Muggia FM; Braly PS; Brady MF; Sutton G; Niemann TH; Lentz SL; Alvarez RD; Kucera PR; Small JM J Clin Oncol; 2000 Jan; 18(1):106-15. PubMed ID: 10623700 [TBL] [Abstract][Full Text] [Related]
42. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622 [TBL] [Abstract][Full Text] [Related]
43. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578 [TBL] [Abstract][Full Text] [Related]
44. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Chambers SK; Chow HH; Janicek MF; Cragun JM; Hatch KD; Cui H; Laughren C; Clouser MC; Cohen JL; Wright HM; Abu Shahin N; Alberts DS Clin Cancer Res; 2012 May; 18(9):2668-78. PubMed ID: 22421191 [TBL] [Abstract][Full Text] [Related]
45. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Ozols RF; Bundy BN; Greer BE; Fowler JM; Clarke-Pearson D; Burger RA; Mannel RS; DeGeest K; Hartenbach EM; Baergen R; J Clin Oncol; 2003 Sep; 21(17):3194-200. PubMed ID: 12860964 [TBL] [Abstract][Full Text] [Related]
46. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. Bookman MA; Greer BE; Ozols RF Int J Gynecol Cancer; 2003; 13 Suppl 2():149-55. PubMed ID: 14656272 [TBL] [Abstract][Full Text] [Related]
47. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference? Cascales-Campos P; López-López V; Gil J; Arévalo-Pérez J; Nieto A; Barceló F; Gil E; Parrilla P Surg Oncol; 2016 Sep; 25(3):164-70. PubMed ID: 27566018 [TBL] [Abstract][Full Text] [Related]
48. Systemic therapy for ovarian cancer: current status and new treatments. Ozols RF Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797 [TBL] [Abstract][Full Text] [Related]
49. The role of intraperitoneal chemotherapy in ovarian cancer. Markman M Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249 [No Abstract] [Full Text] [Related]
50. Ambivalency at the bedside: intraperitoneal chemotherapy. Rodriguez AO Curr Opin Obstet Gynecol; 2007 Feb; 19(1):1-2. PubMed ID: 17218843 [No Abstract] [Full Text] [Related]
51. Intraperitoneal therapy for ovarian cancer: why has it not become standard? Rowan K J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952 [No Abstract] [Full Text] [Related]
52. Current status of chemotherapy for ovarian cancer. Ozols RF Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863 [TBL] [Abstract][Full Text] [Related]
56. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH; Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621 [TBL] [Abstract][Full Text] [Related]
57. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer. Markman M Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295 [TBL] [Abstract][Full Text] [Related]
58. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Bookman MA Semin Oncol; 2002 Feb; 29(1 Suppl 1):20-31. PubMed ID: 11840417 [TBL] [Abstract][Full Text] [Related]
59. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Farley JH; Tian C; Rose GS; Brown CL; Birrer M; Maxwell GL Cancer; 2009 Sep; 115(18):4210-7. PubMed ID: 19536873 [TBL] [Abstract][Full Text] [Related]